SNDA 20-221 ETHYOL FOR RADIATION INDUCED XEROSTOMIA.

Slides:



Advertisements
Similar presentations
First Efficacy Results of a Randomized, Open- Label, Phase III Study of Adjuvant Doxorubicin Plus Cyclophosphamide, Followed by Docetaxel with or without.
Advertisements

Oncologic Drugs Advisory Committee
Modified Megestrol The Clinical Trials by : Carolina R. Akib
Radiotherapy in prostate cancer Dr.Mina Tajvidi Radiation oncologist.
Postoperative Radiation for Oral Cavity Squamous Cell Carcinoma: The EP.
Meeting Agenda Presentations on endpoints –Regulatory issues –Scientific issues Pros and cons of end points –Classical end points –Non-classical end points.
CR-1 Concluding Remarks and Risk/Benefit Summary Mace L. Rothenberg, MD Professor of Medicine Vanderbilt Ingram Cancer Center.
Efficacy of Denileukin Diftitox Retreatment in Patients with Cutaneous T-Cell Lymphoma Who Relapsed After Initial Response 1 Identification of an Active,
1 Tolvaptan for the Treatment of Hyponatremia Aliza Thompson, MD Medical Officer Cardiovascular and Renal Drugs Advisory Committee Meeting June 25, 2008.
Adverse Events, Unanticipated Problems, Protocol Deviations & other Safety Information Which Form 4 to Use?
Comparative Effectiveness and Safety of Radiotherapy Treatments for Head and Neck Cancer Prepared for: Agency for Healthcare Research and Quality (AHRQ)
Intergroup trial CALGB 80101
ODAC SCHERING-PLOUGH RESEARCH INSTITUTE 1 Temozolomide Oncology Drug Advisory Committee March 13, 2003 Craig L. Tendler, M.D. Vice President, Oncology.
1 FDA Review of NDA Valganciclovir for the Treatment of CMV Retinitis in AIDS Joseph Toerner, MD Medical Officer DAVDP.
A Phase II Study to Evaluate the Safety and Toxicity of Sparing Radiation to the Pathologic N0 Side of the Neck in Squamous Cell.
Taxane-pretreated metastatic breast cancer (MBC): investigational agents TTP = median time to disease progression OS = median overall survival.
1 Statistical Perspective Acamprosate Experience Sue-Jane Wang, Ph.D. Statistics Leader Alcoholism Treatment Clinical Trials May 10, 2002 Drug Abuse Advisory.
NDA# Histamine Dihydrochloride FDA Review December 13, 2000.
Hormone Refractory Prostate Cancer A Regulatory Perspective of End Points to Measure Safety and Efficacy of Drugs Hormone Refractory Prostate Cancer Bhupinder.
Phase III studies of Xeloda® in colorectal cancer (CRC)
Role of PCI in Small Cell Lung Cancer Dr. Litan Naha Biswas Apollo Gleanagles Hospital, Kolkata.
NDA ZD1839 for Treatment of NSCLC FDA Review Division of Oncology Drug Products.
Competing Risks in Radiation Oncology Research Biostatistics Lecture June 17, 2010 Elizabeth Garrett-Mayer Amy Wahlquist.
1 Statistical Review Dr. Shan Sun-Mitchell. 2 ENT Primary endpoint: Time to treatment failure by day 50 Placebo BDP Patients randomized Number.
Recent Advances in Head and Neck Cancer Robert I. Haddad, M.D., and Dong M. Shin, M.D. The NEW ENGLAND JOURNAL of MEDICINE N Engl J Med 2008;359:
1 SNDA Gemzar plus Carboplatin Treatment of Late Relapsing Ovarian Cancer.
1 ENTEREG ® (Alvimopan) Special Safety Section Marjorie Dannis, M.D. Division of Gastroenterology Products Office of Drug Evaluation III CDER, FDA The.
Adjuvant radiochemotherapy in head and neck tumors H. Christiansen and C. F. Hess Department of Radiotherapy Goettingen University.
1 Statistics in Drug Development Mark Rothmann, Ph. D.* Division of Biometrics I Food and Drug Administration * The views expressed here are those of the.
Permanent Interstitial Implants Ideal strategy to curatively manage small volume gynecologic malignancies Can deliver high cumulative radiation dose to.
NDA SE-011 Docetaxel FDA Review. FDA Review Team Biostatistics –Clara Chu, PhD. –Gang Chen, PhD. Biopharmaceutics –Safaa Ibrahim PhD –Atiq Rahman,
Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma Marc de Perrot, Ronald Feld, Natasha B Leighl,
Final Analysis of Overall Survival for the Phase III CONFIRM Trial: Fulvestrant 500 mg versus 250 mg Di Leo A et al. Proc SABCS 2012;Abstract S1-4.
Long-Term versus Short-Term Androgen Deprivation Combined with High-Dose Radiotherapy for Intermediate and High Risk Prostate Cancer: Preliminary Results.
Some Design Issues in Microbicide Trials August 20, 2003 Thomas R. Fleming, Ph.D. Professor and Chair of Biostatistics University of Washington FDA Antiviral.
AVADO TRIAL David Miles Mount Vernon Cancer Centre, Middlesex, United Kingdom A randomized, double-blind study of bevacizumab in combination with docetaxel.
High Dose Rate Brachytherapy Boost for Prostate Cancer: Comparison of Two Different Fractionation Schemes Tania Kaprealian 1, Vivian Weinberg 3, Joycelyn.
STUDY 303 A Phase III, Randomized, Multi-Center, Open-Label, 12 to 14 Month Extension Study to Evaluate the Safety and Tolerability of Mesalamine Given.
1 BLA Sipuleucel-T (APC-8015) FDA Statistical Review and Findings Bo-Guang Zhen, PhD Statistical Reviewer, OBE, CBER March 29, 2007 Cellular, Tissue.
‘Arimidex’, Tamoxifen, Alone or in Combination (ATAC) trial: Completed Treatment Analysis.
SNDA Letrozole (Femara®) Indication: First-line therapy in post- menopausal women with advanced breast cancer. Prior approval: Second-line therapy.
Regulatory Considerations for Endpoints Ann T. Farrell, M.D. FDA/CDER/DODP.
Agency Review of sNDA SE-006 DOXIL for Ovarian Cancer Division of Oncology Drug Products Office of Drug Evaluation 1 Center for Drug Evaluation.
Chemoimmunotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) versus Bendamustine and Rituximab (BR) in Previously Untreated and.
CS-1 Update on the Safety of Erythropoietin Products in Patients With Cancer Peter Bowers, MD Senior Director Clinical Team Leader Johnson & Johnson Pharmaceutical.
Journal Club Dr. Eyad Al-Saeed Radiation Oncology 12 January, 2008.
SNDA # GLIADEL® WAFER (Polifeprosan 20 with Carmustine Implant) APPLICANT: GUILFORD PHARMACEUTICALS ODAC: December 6, 2001 Medical Reviewer: Alla.
Pulmonary-Allergy Drugs Advisory Committee May 1, 2007 OutlineOutline History of development programHistory of development program –Dr. Carol Bosken Introduction.
Zometa for Prostate Cancer Bone Metastases Protocol 039 Amna Ibrahim, M.D. Oncology Drug Products FDA.
CLINICAL EFFICACY Oral Telithromycin George Rochester, PhD, CCRN Statistical Reviewer Division of Biometrics III Division of Anti-infective Drug Products.
Carboplatin Not Inferior to Radiation as Adjuvant Therapy for Stage I Seminoma Slideset on: Oliver RT, Mason MD, Mead GM, et al. Radiotherapy versus single-dose.
Reducing excess imaging dose to cancer patients receiving radiotherapy Adam Schwertner, Justin Guan, Xiaofei Ying, Darrin Pelland, Ann Morris, Ryan Flynn.
R2 민준기 / 정재헌 교수님. Introduction Patients with resected high-risk locally advanced head and neck cancer –Expect favorable outcomes after concomitant radiochemotherapy(CCRT)
2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial Aron Goldhirsch, Richard.
Neoadjuvant chemotherapy in the treatment of NSCLC Department of Thoracic Oncology, University Hospital Ghent, Belgium Current Opinion in Oncology 2007,
CCO Independent Conference Coverage*: The 2015 Annual Meeting of the CTRC-AACR San Antonio Breast Cancer Symposium, December 8-12, 2015 San Antonio, Texas.
Slamon D et al. SABCS 2009;Abstract 62.
A cura di Filippo de Marinis
Alessandra Gennari, MD PhD
Statistical Considerations for Safety Assessment in Cancer Immunotherapy Trials Andrew Lloyd Biometrics Manager PSI Conference May 2017.
Slide set on: McCarthy PL, Owzar K, Hofmeister CC, et al
Local Consolidative Therapy in Oligometastatic NSCLC With No Progression on First-line Systemic Treatment CCO Independent Conference Coverage* of the 2016.
A U.S. GI INTERGROUP TRIAL
Benefits of switching postmenopausal women with hormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: Combined results.
Intervista a Filippo de Marinis
1 Verstovsek S et al. Proc ASH 2012;Abstract Cervantes F et al.
1Kantarjian HM et al. Lancet Oncol 2011;12:
RTOG 9704: A Phase III Study of Adjuvant Pre and Post Chemoradiation 5-FU vs. Gemcitabine for Resected Pancreatic Adenocarcinoma A U.S. GI INTERGROUP.
Rarer Bone Tumors Thomas F. DeLaney, M.D. Co-Director: Sarcoma Program
Late-Breaking Data on LDL-C Reduction
Presentation transcript:

sNDA ETHYOL FOR RADIATION INDUCED XEROSTOMIA

REVIEW TEAM

WR-0038 A Phase III Trial of Radiation Therapy  Amifostine in Patients with Head and Neck Cancer

PRETREATMENT CHARACTERISTICS Balanced Site of Disease Clinical Stage Nodal Status Volume of Parotid Glands for RT Type of Radiation

INTENDED RADIATION DOSE “Type of Radiation” Inoperable Gy Post-Operative, High-Risk60-66 Gy Post-Operative, Low-Risk50-60 Gy

ACTUAL RADIATION RECEIVED Overall : p=0.056

PRIMARY ENDPOINTS

PRIMARY ENDPOINT: Acute Xerostomia Applicant: Significant Reduction of Grade 2 Xerostomia –A+RT (51%) vs. RT (78%) (p<0.0001) FDA: Agree No difference in overall incidence (Gr 1 + 2) –A+RT (90%) vs. RT (94%) (p=0.07)

PRIMARY ENDPOINT: Late Xerostomia Applicant: 365  31 days Significant Reduction in Grade 2 or greater –A+RT (34%) vs. RT (57%) (p<0.0019) FDA Comments: –Disagree with applicant’s definition –Reanalysis necessary

FDA Review (revised): Late Xerostomia

LATE XEROSTOMIA vs. TOTAL RADIATION DOSE

PRIMARY ENDPOINT: Acute Mucositis No difference (Grade 3 or greater) –A+RT (35%) vs. RT (39%) (p=0.48) Grade 1 to 4 –A+RT (95%) vs RT (99%)

SUMMARY OF PRIMARY EFFICACY ENDPOINT FINDINGS  Significantly lower incidence of moderate acute xerostomia  Significantly lower incidence of moderate to severe late xerostomia  No difference in the incidence of acute mucositis

SECONDARY ENDPOINTS Related to Efficacy: –Saliva Measurements –Patient Benefit Questionnaire Related to Non-Tumor Protection: –One Year Locoregional Control (Primary Endpoint) – DFS –Overall Survival Safety

Applicant: Significant difference in unstimulated saliva at one year (> 0.1 gm) –A+RT (72%) vs. RT (49%) (p=0.003) Not confirmed by stimulated saliva collections –A+RT (33%) vs. RT (41%) (p=0.3) SECONDARY ENDPOINT Saliva Measurements FDA Comments: Longitudinal analysis of unstimulated saliva production non-confirmatory Retrospective definition of time point comparisons Retrospective definition of clinically significant cut-off values

FDA ANALYSIS: Change from Baseline

SUMMARY OF SECONDARY EFFICACY ENDPOINT FINDINGS: Saliva Measurements

SECONDARY ENDPOINT: Patient Benefit Questionnaire Reasons for Different Analyses FDA Analysis Results Summary

Analysis of PBQ Data Different measures of clinical benefit –Sponsor: mean score of 8 questions –FDA: 3 individual subscales Functional well-being (speaking, eating) General condition (dryness) Use of external aids (frequency of fluid intake for eating & comfort not associated with eating) Number of data points –Sponsor: excluded data beyond the 1 year follow-up visit –FDA: all data points

FDA Analysis of PBQ Data Cutoff value in defining dropouts and completers: 1 year Number of Patients Method: Longitudinal analysis with GEE quadratic models

Functional Well-being Completers & Dropouts GEE quadratic model

General Condition Completers & Dropouts GEE quadratic model

Use of External Aids Completers & Dropouts GEE quadratic model

Functional Well-being All Patients

General Condition All Patients

Use of External Aids All Patients

SUMMARY Results: Descriptive and exploratory –Subjective nature of the questionnaire –Open-label trial design –Adjustment of multiple comparisons Trends in favor of the Ethyol: –General Condition –Use of External Aids Trend in favor of the Ethyol arm for Functional Well-being ?

Applicant: –Primary: no difference in locoregional control at one year (72% vs. 71%, p=1.0) –no difference in DFS, overall survival –WR-9001 in Rectal Cancer: no significant difference in overall survival SECONDARY ENDPOINT Tumor Control FDA Comments: –WR-0038: immature data, high censor rate –Selection of 0.7 as the lower limit of a 1-sided C.I. is liberal

Significantly greater frequency of known adverse events Large number of dropouts in A+RT –29/150 (19%) More radiotherapy doses missed in A+RT More hospitalizations in A+RT –A+RT:101 vs. RT:63 SAFETY

CONSIDERATIONS FOR APPROVAL Well-designed, well-controlled trials Substantial evidence of efficacy and safety

!Significant but expected toxicities !More drop-outs, hospitalizations, missed doses !Ability to deliver optimal doses of therapy and potential effect on the efficacy ? !Should be weighed against strength of other evidence i Safety

 Significant difference in moderate to severe acute and late xerostomia  PBQ and Salivary Measurement data supportive ? i Efficacy

 Single phase 3 trial i Adequate and well controlled clinical trials